Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies ... http://investorplace.com/2014/01/6-biotechnology-stocks-to-sell-now-tsro-tsrx-plx/.
Avago expects the acquisition to add immediately to non-GAAP earnings per share and anticipates “driving the PLX business to a level consistent with Avago’s long term business model by the end of fiscal year 2015.” Avago’s stock is …
Investors in Protalix BioTherapeutics, Inc. PLX need to pay close attention to the stock based on moves in the options market lately. That is because the November 11 th, 2017 $2 Call had some of the highest implied volatility of all equity …
San Jose-based Integrated Device Technology reached a deal on April 30 to purchase PLX Technology for cash and stock totaling $330 million — and the two companies have been trying to win Federal Trade Commission approval since then. …
This is the second time in three months that a patient suffering from bone marrow failure was successfully treated with its PLX cells, the Israeli company ... failed bone marrow transplants, sending its stock up 32 percent.
New York, NY -- (SBWIRE) -- 07/25/2017 -- Proven efficacious as an antidote for Acute Radiation Syndrome (ARS) with data recently published from studies conducted by the U.S. National Institutes of Health (NIH), Pluristem Therapeutics' …
Dec 22 (Reuters) - Dipexium Pharmaceuticals Inc : * Dipexium Pharmaceuticals -following closing, dipexium will be renamed PLX Pharma Inc ... of common stock of Dipexium * Dipexium and PLX Pharma announce merger
Protalix Biotherapeutics Inc. (AMEX:PLX; TASE: PLX) today reported that its treatment for ... Protalix's share price closed at $6.51 on the American Stock Exchange yesterday, giving a market cap of $557 million. There is no trading on the …
Salix is seeking to have Xifaxan approved to treat certain types of irritable bowel syndrome. Shares of Protalix BioTherapeutics Inc. PLX, +1.15% slipped 2%. The Israel-based drug maker is expected to hear by late Friday whether …